Additionally, overexpression of IRF7 in prostate cancer cells inhibits bone metastases through IFNI-induced NK activation [85], while loss of host IFNI receptor signaling in vivo blocks NK-mediated anti-tumor immune responses and results in increased cancer cell metastasis [86,87,88]. Here, IRF7 is linked to neoplasm.